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Islet transplantation in diabetes is hampered by the need of life-long immunosuppression. Encapsulation provides partial
immunoprotection but could possibly limit oxygen supply, a factor that may enhance hypoxia-induced beta cell death in the early
posttransplantation period. Here we tested susceptibility of alginate microencapsulated human islets to experimental hypoxia (0.1–
0.3% O
2
for 8 h, followed by reoxygenation) on viability and functional parameters. Hypoxia reduced viability as measured by
MTT by 33.8 ± 3.5% in encapsulated and 42.9 ± 5.2% in nonencapsulated islets (𝑃 < 0.2). Nonencapsulated islets released 37.7%
(median) more HMGB1 compared to encapsulated islets after hypoxic culture conditions (𝑃 < 0.001). Glucose-induced insulin
release was marginally affected by hypoxia. Basal oxygen consumption was equally reduced in encapsulated and nonencapsulated
islets, by 22.0 ± 6.1% versus 24.8 ± 5.7%. Among 27 tested cytokines/chemokines, hypoxia increased the secretion of IL-6 and
IL-8/CXCL8 in both groups of islets, whereas an increase of MCP-1/CCL2 was seen only with nonencapsulated islets. Conclusion.
Alginate microencapsulation of human islets does not increase susceptibility to acute hypoxia. This is a positive finding in relation
to potential use of encapsulation for islet transplantation.
1. Introduction
Transplantation of pancreatic islets containing the insulin-
producing beta cells could in principle cure type 1 diabetes.
However, transplantation of allografts necessitates treatment
with immunosuppressant drugs with ensuing side effects.
Encapsulation of islets (or isolated beta cells) could poten-
tially alleviate this problem, thus motivating previous and
ongoing research on the feasibility of encapsulated islets
for successful transplantation. Promising results (reversal of
diabetes in animalmodels of diabetes) have been reported [1–
4]. However, questions remain as to both the short and long
term functionality of encapsulated islets or beta cells.
One question pertains to the impact of hypoxia on
encapsulated islets. Native pancreatic beta cells have high
rates of oxidative metabolism to meet the demand of insulin
production and secretion [5], and evenmoderately decreased
levels of oxygen have been shown to inhibit insulin release
[6]. Hypoxia after transplantation is a major (albeit not
the only) contributor to the dramatic drop of viable beta
cells (nonencapsulated) that occurs in the immediate period
following transplantation [7–10]. A negative impact of the—
inevitable—hypoxia during the immediate period following
transplantation could possibly be worsened by encapsulation,
since the distance of diffusion for oxygen could be greater in
encapsulated versus nonencapsulated islets (or amassed beta
cells) [11, 12], and a negative effect of clustering of islets may
occur [13]. Comparisons of oxygen uptake in encapsulated
versus nonencapsulated islets have been done for neonatal
porcine [14] and pig [15] islets in vitro (normoxic conditions)
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without unveiling negative effects of encapsulation, while
encapsulation of rat islets led to a significant reduction of
oxygen uptake [16]. However, a similar comparison has,
to the best of our knowledge, not been made for human
islets, neither in a setting of normoxic nor hypoxic culture
conditions.
The aim of the present study was to compare viability
and functional parameters of encapsulated versus nonen-
capsulated islets during normoxic culture conditions and in
particular after a defined period of hypoxia. We chose an in
vitro approach, since testing could be influenced by site for
transplantation, therebymodifying a basic impact of hypoxia.
We used alginate microbeads, since such a preparation has
recently been shown to be a promising candidate for immune
protection in light of its low inflammatory potential [17, 18] as
well as functional performance inmicemodels [1, 2]. A recent
study using similarmicrobeads highlights beneficial effects of
encapsulation on human islet functionality [4].
2. Materials
Ultrapure sodium alginate from Laminaria hyperborea,
Pronova UP-LVG (67% guluronic acid, viscosity 1051mL/g,
endotoxin 23 EU/g, MW 187 × 103) was from Nova-Matrix,
Oslo, Norway. Other materials were from Sigma-Aldrich
Chemicals Co. (St. Louis, MO) or from sources specified
below.
3. Methods
3.1. Islet Procurement, Isolation, and Shipment. Human islets
were isolated at the Division of Transplant, University of
Illinois, Chicago, as previously described [19, 20] and shipped
to Trondheim. Sustained function of shipped human islets
has previously been documented [1]. The purity and viability
(determined on the basis of dithizone staining) and insulin
secretion at the time of shipment as well as donor charac-
teristics are presented in Table 1. Totally 5 shipments were
received, each shipment containing islets from a single donor.
The Regional Committee for Medical and Health Research
Ethics Central, Norway, approved the procurement of human
islets and their use for research. Only islets from donors with
research consent were used.
3.2. Islet Culture and Microencapsulation. Upon arrival in
Trondheim, islets were centrifuged (1000 rpm, 2min) and
resuspended in RPMI 1640 medium containing 5.5mM
glucose and supplemented with 10% fetal calf serum (FCS),
10mM HEPES, 4mM L-glutamine, 1mM sodium pyruvate,
100 IU/mL penicillin, and 100 𝜇g/mL streptomycin. Islets
were cultured in flasks at 37∘C in a humidified atmosphere
of 5% CO
2
in air.
The number of islets was estimated after overnight
culture. One half of the islets was then encapsulated in
alginate, while the other half remained nonencapsulated. For
encapsulation, 10–20 000 islet equivalents were centrifuged
(1000 rpm, 2min) and resuspended in 300–400 𝜇L of RPMI
with 5.5mM glucose. They were then added to 1.8mL of
Table 1: Donor and donor islet characteristics.
Purity (%) Viability (%) GSI prior toshipment Age (years) BMI
87.3 ± 2.7 93.0 ± 0.6 2.1 ± 0.4 46.4 ± 4.8 30.2 ± 2.7
(80–95) (91–95) (1.24–3.22) (32–59) (22.6–40.8)
Data are mean ± SEM (range), 𝑛 = 5.
GSI equals glucose stimulation index.
2.0% sterile filtered UP-LVG alginate (in 0.3M mannitol, pH
7.3). Inhomogeneous alginatemicrobeadswere formed by use
of an electrostatic bead generator (7 kV, one 0.4mm needle,
flow 10mL/h) using a gelling solution of 50mMCaCl
2
, 1 mM
BaCl
2
, 150mM mannitol, and 10mM HEPES, at pH 7.3. The
microbeads (521 ± 10 𝜇m in diameter, measurements from
33 capsules, each containing 1–4 islets) were collected on a
filter and then washed three times with 12mL of Hank’s and
once with 20mL of culture media before being transferred
to a culture flask. Both encapsulated and nonencapsulated
islets were cultured overnight and used for experiments 1–23
days later. We did not observe clumping of nonencapsulated
islets to any major extent. Further, we did not detect obvious
differences due to length of culture on function and viability
neither in encapsulated nor in nonencapsulated islets.
3.3. Experimental Protocols. Prior to each experiment,
aliquots from homogenous suspensions of encapsulated and
nonencapsulated islets were collected to estimate the number
of islets per mL culture media.
Encapsulated and nonencapsulated islets were divided
into each of two groups and transferred to Petri dishes (with
<100 islets per 5mL culture medium) before exposure to
either continuous normoxia or to 8 h of hypoxia followed by
14–18 h of reoxygenation. Hypoxia was induced by placing
islets in a hypoxia chamber (Billups-Rothenberg Inc., Del
Mar, CA) together with an oxygen monitor (Dra¨ger Safety
AG & Co., KGaA, Lu¨beck, Germany) and a Petri dish with
5–10mL of water for humidity. The chamber interior was
flushed with nitrogen gas (95% N
2
, 5% CO
2
) until a level of
0.1% O
2
was reached. After 8 hours of incubation the oxygen
concentration inside the chamber had risen to 0.2-0.3%.
For each of the four different experimental conditions
(i.e., normoxia or hypoxia for encapsulated and normoxia
or hypoxia for nonencapsulated islets) a control estimate
of islet number per dish was made also after the end of
the reoxygenation period. Islets from the different culture
conditions, as well as aliquots of culture media, were sampled
for measurements as detailed below.
3.4. MTT. For each experimental condition, 30 or 40
islets (encapsulated as well as nonencapsulated) were hand-
picked into each of 2–5 parallel wells on a 24-well plate
for 4 h of exposure to 3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyltetrazolium bromide (MTT). The MTT reagent in
the media was removed by washing the islets several times in
0.9% NaCl. Islets were then incubated for one hour in 400 𝜇L
DMSO per well at 37∘C for color development. Fifty 𝜇L/well
of 0.1M NaCl in 0.1M Glycine, pH 10.5, was added for color
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extraction. Two parallel aliquots per well were secured for
absorbance measurements.
3.5. HMGB1. The amount of high mobility group box 1
(HMGB1) in media aliquots (kept at −80∘C until assay) was
measured by a HMGB1 ELISA kit (IBL International, Ham-
burg, Germany). The assay was performed as recommended
by the producer.
3.6. Insulin Secretion. Groups of 5 handpicked islets were
placed in each of 5-6 parallel wells in a 24-well plate. This
was followed by preincubation for 30min at 37∘C in 0.5mL of
Krebs-Ringer bicarbonate buffer (KRB, containing 0.5% BSA
and 10mM HEPES at pH 7.4) together with 1.6mM glucose.
Islets were transferred into a new 24-well plate and incubated
for another 60min in KRB containing 1.6mM glucose in
order to assess basal (= un-stimulated) insulin secretion.The
same islets were finally transferred to a new 24-well plate for
stimulated insulin secretion by incubation for 90min in KRB
with 16.7mM glucose. Aliquots of incubation media were
secured for basal aswell as stimulated secretion. Sampleswere
kept at −20∘C pending insulin measurements by a RIA kit for
human insulin (Millipore, St. Charles, MO).
3.7. Oxygen Consumption. Equal amounts of islets were
transferred to each of three dishes and exposed to hypoxia
for 8 h followed by 14–18 h of reoxygenation. Control islets
were cultured continuously at normoxia. For each condition
islets (3x approx. 300 islets) were pooled into one sample
immediately before the oxygen consumption measurements.
Oxygen consumption was measured by Clark-type
polarographic oxygen sensors and high-resolution respirom-
etry (Oxygraph-2k, OROBOROS, Innsbruck, Austria). Sam-
ples of up to 900 islets in culture medium (corresponding
to ∼106 islet cells/cm3) were added to a chamber. Islets were
allowed to sediment before closing the chamber, switching on
magnetic stirring and recording oxygen uptake at basal respi-
ration.TheATP synthase inhibitor oligomycin (2𝜇g/mL)was
subsequently added with the aim to assess uncoupled (= not
ATP-coupled) respiration. After that, the protonophore car-
bonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP)
was added and titrated (up to 5-6𝜇M) to achieve a state
of maximum respiratory capacity. Finally, rotenone (0.5𝜇M)
and antimycin (2.5 𝜇M), inhibitors of mitochondrial com-
plexes I and III, were added in order to measure residual
oxygen consumption (ROX). Oxygen consumption rates
were calculated as the negative time derivate of the oxygen
concentration present in the chamber (pmol/s/mill cells). For
all experiments, ROX values were close to zero.
3.8. Cytokine/Chemokine Measurements. For all islet culture
conditions, aliquots of the culture media were harvested
after the reoxygenation period. For a subset of experiments,
aliquots of media were secured also immediately after the
time of hypoxia exposure. Samples were kept at −80∘C until
assays were performed.
Islet secreted mediators were analyzed by a multiplex
bead-based cytokine assay (Bio-PlexHumanCytokineGroup
I 10-Plex Panel, Bio-Rad Laboratories, Hercules, CA) con-
taining the following analytics: IL-1ra, IL-6, IL-8/CXCL8, IL-
9, IL-10, IL-12(p70), GM-CFS, MCP-1/CCL2, MIP-1𝛽/CCL4,
and VEGF. In addition, we included Bio-Plex kit reagents
for detecting MIF, a part of Human Cytokine Group II.
Our panel of mediators was chosen on the basis of pre-
analyzed samples (from each of the four conditions) using
a Bio-Plex Human Cytokine Group I 27-plex panel (Bio-
Rad Laboratories, Hercules, CA). The following analytics
were below the detection limit and therefore excluded from
the main analyses; IL-1𝛽, IL-2, IL-4, IL-5, IL-13, IL-15, IL-
17, Eotaxin/CCL11, Basic FGF, IFN-𝛾, IP-10/CXCL10, MIP-
1𝛼/CCL3, PDGF-BB, Rantes/CCL5, and TNF-𝛼. The mul-
tiplex analyses were performed as recommended by the
producer except for using half the recommended amounts
of beads. For intra-assay variations, see Supplementary
Table S1 of the Supplementary Material available online at
http://dx.doi.org/10.1155/2013/374925.
3.9. Microbead Dissolution, Extraction, and Measurement of
DNA. To assess DNA contents microcapsules first had to
be completely dissolved. Dissolving of alginate microbeads
(350 𝜇L) was achieved by adding 1000 𝜇L of tetra sodium
EDTA (50mM, pH 8) at 37∘C followed by intermittent
vortexing for up to 30 minutes. After centrifugation (10min,
13000 rpm), the islet pellet was harvested and resuspended
in water for extraction of DNA. Nonencapsulated islets were
extracted by the same procedure. DNA was quantified by
the Fluorescent DNA Quantification kit (Bio-Rad, Hercules,
CA).
4. Statistics
Data are presented as mean ± SEM. Also medians were
calculated. The Wilcoxon rank test was used for significance
testing. A 𝑃 value < 0.05 was defined as statistically signifi-
cant.
5. Results
5.1. MTT. Islet viability assessed by MTT is presented in
Table 2. The mean absorbance values were identical for
encapsulated and nonencapsulated islets after continuous
normoxia. Previous hypoxia exposure significantly reduced
the MTT parameter of viability in both groups of islets by
33.8 ± 3.5% versus 42.9 ± 5.2% (𝑃 < 0.2 for difference). There
was thus no tendency for a stronger effect of hypoxia in the
encapsulated islets.
5.2. HMGB1. Hypoxia-induced islet damage has been associ-
ated with HMGB1 release [21, 22].The release of HMGB1 was
therefore used as a marker for islet destruction. Compared
to encapsulated islets, nonencapsulated islets released 22.4 ±
13.3% more (𝑃 < 0.2) HMGB1 under continuous normoxia.
Levels of HMGB1 were significantly increased in media from
both groups of islets after experimental hypoxia by 37.2 ±
15.2% (median: 35.0%) for encapsulated and by 39.7 ± 28.7%
(median: 33.3%) for nonencapsulated islets (𝑃 < 0.2 for
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Table 2: Absorbance values (570 nm) representing islet viability measured by MTT.
Encapsulated islets Non-encapsulated islets
Normoxia Hypoxia Reduction by hypoxia (%) Normoxia Hypoxia Reduction by hypoxia (%)
0.15 ± 0.02 0.10 ± 0.01
∗
33.8 ± 3.50 0.15 ± 0.02 0.09 ± 0.02
∗
42.9 ± 5.20
∗
𝑃 < 0.002 for the effect of hypoxia, 𝑃 < 0.2 for the comparison of hypoxia-induced reduction of viability for encapsulated versus non-encapsulated islets.
Data are mean ± SEM for 12 separate experiments (two-five parallels per condition), one-four experiments per donor (five donors).
0
5
10
15
20
25
30
1.6
(mM)
16.7
Encapsulated, normoxia Encapsulated, hypoxia
Nonencapsulated, normoxia Nonencapsulated, hypoxia
#
ns
$
¤¤
$
$ $
In
su
lin
 se
cr
et
io
n 
(𝜇
U
/is
le
t/w
el
l)
∗
Figure 1: Effect of hypoxia and encapsulation on insulin secretion
at 1.6 and 16.7mM glucose. $𝑃 < 0.02 for the stimulatory effect of
16.7mM glucose, ∗𝑃 < 0.02 for the effect of hypoxia, ¤𝑃 < 0.04 for
the effect of encapsulation, and #𝑃 < 0.02 for the effect of hypoxia on
encapsulated versus nonencapsulated islets at basal secretion. Data
are mean ± SEM of eight separate experiments (five-six parallels
per experimental condition), one-three experiments per donor (four
donors).
difference, 𝑛 = 13). However nonencapsulated islets released
in total 43.1 ± 9.3% (median: 37.7%) more HMGB1 than
encapsulated islets under hypoxic culture conditions (𝑃 <
0.001, 𝑛 = 13).
5.3. Insulin Secretion. Insulin release during normoxia and
low glucose (1.6mM) was modest (in comparison to stimu-
lated insulin release) for both encapsulated and nonencapsu-
lated islets (Figure 1). Secretion in this unstimulated state was
somewhat higher in encapsulated versus nonencapsulated
islets conditions (𝑃 < 0.04). During the same conditions
of oxygen supply (normoxia, no previous hypoxia) raising
the glucose concentration to 16.7mM elicited a strong (10–
14-fold) insulin response in both types of islet preparations.
The fold increase due to 16.7mM glucose, named the glucose
stimulation index (GSI), was lower in encapsulated than in
nonencapsulated islets (10.0 ± 3.1 versus 15.9 ± 4.7, 𝑃 <
0.04). Interestingly, the GSI after shipment and culture in
Trondheim for various times was higher than GSI after
isolation, as recorded in Table 1.
After exposure to hypoxia, insulin secretion at low
glucose concentrations increased in nonencapsulated islets
(𝑃 < 0.04) but not in encapsulated islets (Figure 1).
Hypoxia did not affect the stimulatory effect of 16.7mM
glucose in absolute terms of insulin secretion whether in
nonencapsulated or encapsulated islets. However, due to the
increased insulin secretion during low glucose, the hypoxia-
induced reduction of the GSI was more pronounced in
nonencapsulated islets (68.7±6.1%, from 15.9±4.1 to 3.9±0.9,
𝑃 < 0.02) than in encapsulated islets and (24.5 ± 11.2%, from
10.0 ± 3.1 to 6.3 ± 1.1, ns).
5.4. Oxygen Consumption. The oxygen consumption in
encapsulated and nonencapsulated islets following culture
under normoxia or transient hypoxia is shown in Figure 2.
At basal conditions after continuous normoxia oxygen con-
sumption appeared slightly but not significantly higher in
encapsulated versus nonencapsulated islets. Exposure to
hypoxia reduced oxygen consumption both in encapsulated
(by 22.0 ± 6.1%) and nonencapsulated islets (by 24.8 ± 5.7%,
𝑃 < 0.7 for comparison). Compared to basal respiration,
addition of FCCP (an inducer of maximal respiration capac-
ity) led to a modest increase in oxygen uptake for islets
subjected to all four culture conditions. Hypoxia tended
to reduce FCCP-induced respiration (by 9.7 ± 13.1% in
encapsulated and by 2.9 ± 6.9% in nonencapsulated islets,
𝑃 < 0.3 for comparison) (Figure 2).
The lack of a “plateau” of oxygen uptake following the
administration of oligomycin A (results not shown) ham-
pered a more detailed analysis of the impact of hypoxia on
oxygen consumption.
Islet DNA contents were measured in two represen-
tative experiments. Encapsulated islets contained a mean
of 3.19 𝜇g DNA/sample and nonencapsulated islets 2.31 𝜇g
DNA/sample. Corresponding values obtained after hypoxia
were 2.63 and 2.12 𝜇g DNA/sample. These differences in
DNA content parallel the slightly (ns) higher basal oxygen
uptake seen in encapsulated versus nonencapsulated islets in
Figure 2 (+19.8 ± 12.8% for normoxia and +13.6 ± 17.2% for
hypoxia).
5.5. Cytokine/Chemokine Secretion. Themost secreted medi-
ators detected by the multiplex analysis were IL-6, IL-
8/CXCL8, MCP-1/CCL2, IL-9, IL12, and VEGF.The secretion
profiles of these mediators from encapsulated and nonen-
capsulated islets after culture under normoxic and transient
hypoxic conditions are given in Figure 3. The accumulation
(pg or fg/islet/22–26 h) of IL-8/CXCL8, IL-9, and MCP-
1/CCL2 was significantly increased from encapsulated versus
nonencapsulated islets under basic normoxic conditions.The
opposite tendency (reduced accumulation for encapsulated
versus nonencapsulated islets) was seen for IL-12 (significant)
and VEGF (nonsignificant). Experimental hypoxia signifi-
cantly enhanced the accumulation of IL-6 and IL-8/CXCL8
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Figure 2: Effect of hypoxia and encapsulation on oxygen consump-
tion. ∗𝑃 < 0.05 for the effect of hypoxia and #𝑃 < 0.05 for the
effect of FCCP versus basal respiration. Data are mean ± SEM of
five-six separate experiments (one-three parallels per experimental
condition), one-two experiments per donor (four donors).
for both groups of islets, whereas the secretion of MCP-
1/CCL2 was significantly increased from nonencapsulated
while unchanged from encapsulated islets. Hypoxia did not
affect the accumulation of IL-9 from neither group of islets.
The secretion of IL-12 and VEGF was significantly reduced
from nonencapsulated islets and unchanged for encapsulated
islets.
The ratios of hypoxia-induced accumulation of cytok-
ines/chemokines (H) divided by the accumulation during
continuous normoxia (N) (H/N ratio) are summarized in
Table 3. Notably, the hypoxia-induced enhancement or re-
duction of presented mediators was less pronounced for
encapsulated islets versus nonencapsulated islets. Hence, the
H/N ratios were closer to unity for encapsulated islets.
Levels of IL-1ra, IL-10, GM-CSF, MIP-1𝛽/CCL4, and
MIF were close to the detection limit. These data are pre-
sented as Supplementary Figure S1 and Table S2. Significant
effects of encapsulation were seen during basic conditions
for MIP-1𝛽/CCL4 and MIF (increased secretion) and IL-10
(decreased).
We also wished to address the question whether hypoxia-
induced changes/alterations of the accumulation of cytokines
take place mainly during the hypoxic event or following
hypoxia (i.e., during reoxygenation). We compared in a
subset of experiments, 𝑛 = 4 (representing two experiments
for each of two donors/islet isolates), the accumulation
during the 8 h of hypoxia with that whichwas secreted during
the hypoxia + reoxygenation period. The data presented
in Supplementary Table S3 show that the secretion of IL-
6, IL-8/CXCL8, MCP-1/CCL2, and VEGF continue to a
large extent during the reoxygenation period. The most pro-
nounced lingering effect of hypoxia was seen for IL-6. From
nonencapsulated islets almost 90% was secreted during the
time period of reoxygenation. Secretion differences between
the hypoxia and the reoxygenation period tended to be less
pronounced for encapsulated islets (Supplementary Table S3
and Supplementary Table S4). For IL-9 and IL-12 the secreted
levels after 8 h of hypoxia were hardly detectable.
6. Discussion
Our results indicate, in general, that the impact of acute and
severe hypoxia is no more negative for microencapsulated
than for nonencapsulated human islets whether in terms
of viability or function. In fact the effects of hypoxia on
some parameters (MTT, HMGB1, and cytokines) were less,
or tended to be less, marked in the encapsulated islets. The
relevance of these findings would appear strengthened by the
human islets being of high purity and displaying at the onset
of experiments good function in terms of glucose-induced
insulin secretion and oxygen consumption.
HMGB1 is secreted from human islets as a response to
islet damage [21] and is recently shown to be secreted during
hypoxia [22]. Our data confirm increased levels of HMGB1
secretion after hypoxic culture conditions, a finding shared
by encapsulated andnonencapsulated human islets.However,
we find less total secretion of HMGB1 from encapsulated
versus nonencapsulated islets after hypoxia exposure. This
suggests that the microcapsule could have a protective effect
against islet destruction. As a further implication, one may
note that HMGB1, due to its inflammatory properties of
[23, 24], might be a contributor to the fibrotic responses
against encapsulated islets, such responses being a major
challenge in islet encapsulation based therapy. Also in this
respect the lower secretion of HMGB1 from encapsulated
islets could possibly be viewed as a positive finding. It should
however be emphasized that the direct impact of HMGB1
in human islet transplantation has recently been questioned
[21].
The insulin data point to subtle effects of encapsula-
tion and in particular a slightly increased secretion dur-
ing basal normoxic conditions. The cause(s) behind this
difference has not been elucidated. Based on the hypoxia-
induced rise in basal insulin release that we observe for
nonencapsulated islets, one possible explanation could be
that islets within the microcapsule are subjected to mild
hypoxia, which subsequently gives rise to the basal secretion.
Data from Vaithilingam et al. could support such notion
since pretreatment with the hypoxia-mimicking desferriox-
amine agent induces slightly elevated basal insulin secretion
[25].
A high degree of oxygen consumption recorded in vitro
has been linked to successful transplantations [26–28]. It is
thus a positive finding (in terms of the clinical utility of
encapsulated islets) that oxygen consumption under basic
conditions (no hypoxia) was not diminished in encapsulated
islets (Figure 2).These findings are in linewith those reported
previously for pig islets encapsulated in a monolayer cellular
device [15] and for microencapsulated neonatal porcine islets
[14]. The recorded values of oxygen flux (pmol/s/mill cells)
in our study are comparable to the findings for rat islets by
6 Journal of Diabetes Research
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Figure 3: Secreted mediators from encapsulated (E) and nonencapsulated (N-E) islets following culture in continuous normoxia (open
bars) and transient hypoxia (filled bars). ∗𝑃 < 0.03 and ∗∗𝑃 < 0.001 for the effect of hypoxia, #𝑃 < 0.05 and ##𝑃 < 0.003 for the effect
of encapsulation during normoxia. Data are mean ± SEM of 13 separate experiments (one sample per condition), one-five experiments per
donor (five donors).
use of the same type of oxygraph [29]. As to the hypoxia-
induced decrease in oxygen consumption that we find, this
was anticipated fromprevious studies on nonencapsulated rat
islets [30]. Importantly, the decrease in oxygen consumption
due to hypoxia was not aggravated by microencapsulation.
The production and secretion of cytokines and chemok-
ines are thought to reflect, in part at least, the impact of
stressors on islets [31]. Cytokines and chemokines are of
general importance in graft destruction due to their vari-
ous roles in inflammation, angiogenesis, and microcapsule
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Table 3: Effect of hypoxia on islet secreted mediators by H/N ratios (fold increase by hypoxia).
Encapsulated islets Nonencapsulated islets
Mean ± SEM Median Mean ± SEM Median
IL-6 3.52 ± 0.80∗ 2.48 28.43 ± 24.22∗a 4.66
IL-9 0.97 ± 0.11 1.01 1.09 ± 0.17 0.95
IL-12 0.88 ± 0.07 0.93 0.69 ± 0.09∗# 0.71
IL-8 1.59 ± 0.23∗ 1.39 3.19 ± 0.79∗# 2.11
MCP-1 1.12 ± 0.09 0.98 1.40 ± 0.15∗# 1.31
VEGF 0.91 ± 0.06 0.88 0.70 ± 0.07∗# 0.72
∗
𝑃 < 0.001–0.05 for the effect of hypoxia, #𝑃 < 0.01–0.05 for the comparison of encapsulated versus non-encapsulated islets. Data are based on 11–13 single
experiments (one sample per condition), one-five experiments per donor (five donors). aMean ± SEM contains one outlier value. Excluding the outlier changes
mean ± SEM to 5.23 ± 1.19 and median to 4.14.
H/N equals ratio of hypoxic to normoxic conditions.
fibrosis. It was therefore of interest to compare the secretion
of these biologically active substances from encapsulated and
nonencapsulated islets.
Of the cytokines/chemokines that could be reliably mea-
sured, we found that IL-6, IL-8/CXCL8, IL-9, and MCP-
1/CCL2 were increased, or tended to be, by encapsulation,
whereas IL-12 and VEGF tended to be decreased. IL-6 is
generally known as a strong proinflammatory cytokine but
is also shown to have anti-inflammatory properties [32, 33].
Various regulatory roles of immune responses are also found
for IL-9 [34] and IL-12 is an important regulator of helper T
cells [35]. IL-8/CXCL8 is a strong attractor for neutrophils
[36] and contributes to angiogenesis [37]. VEGF is a key
proangiogenic growth factor [38, 39]. MCP-1/CCL2 is an
important chemokine in attraction of monocytes and has
been negatively associated to graft function [40].
It should be noted that secretion of VEGF was decreased
in response to hypoxia rather than increased. At first glance
this finding in nonencapsulated islets is paradoxical, since
treatment of human islets with the hypoxia-mimicking agent
desferrioxamine increased the expression of VEGF [25].
However, a study with islets indicated that a 48 h culture in
normoxia increased VEGF mRNA and protein to an extent
that further increase was not observed after hypoxia [41].
Possibly, cells in the core of hypoxic islets have been damaged
to an extent which could have impaired their production and
secretion of VEGF. Also, our finding is in line with a previous
paper showing reduced secretion of VEGF in response to a
different stressor, that is, enterovirus infection [42]. It seems
clear that the regulation of VEGF by different stressors under
different experimental conditions needs to be studied further.
In general, the hypoxia-induced enhancement of cytoki-
ne/chemokine secretion appeared less marked from encap-
sulated islets. This could, in part at least, be secondary
to the somewhat higher secretion during normoxic (no
previous hypoxia) conditions. Whether this indicates that
encapsulation induces more stress during basic conditions
of culture cannot be decided. Speaking against such notion
are the viability, oxygen consumption, and insulin data. In
any case the data provided here do not indicate enhanced
cytokine/chemokine responses to hypoxia in encapsulated
versus nonencapsulated islets.
There are limitations to the study.With islets from a larger
number of donors one could possibly have detected addi-
tional subtle differences between encapsulated and nonen-
capsulated islets. Further, one should acknowledge that we do
not know which cells in the islet preparations that actually
release the cytokines/chemokines. For IL-8/CXCL8 it has
been shown that this cytokine can be produced by human
𝛽-cells [31]. Yet, clinically this uncertainty may be of less
importance, since all cells that are part of an islet preparation
will be transplanted. Also different encapsulation protocols
have been used in previous studies, and we did not test for
potential effects of such differences in the present context.
However, the composition of alginate employed here has
been widely used in recent years and transplantations of
islets in similar microcapsules have given promising results
in animal models of diabetes [1, 2, 4], and future clinical
studieswith such capsules seemclinically relevant [4]. Finally,
one cannot a priori extrapolate the present findings in
vitro to a more complex in vivo situation. However, in a
scenario inwhich one or several aspects of the transplantation
of encapsulated islets are not successful the present data
should be helpful in “problem-shooting” by minimizing the
possibility of increased sensitivity to hypoxia.
7. Conclusions
This in vitro study has revealed subtle functional differences
between alginate-encapsulated and free islets but none of
these differences indicate that encapsulation increases sus-
ceptibility to negative effects of acute hypoxia. Indeed, the
outcome of several parameters indicates better resilience
towards hypoxia. This is a positive finding in relation to
potential use of encapsulation for islet transplantation.
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